Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

2 Jun 2011
Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

2 Jun 2011
Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

1 Jun 2011
Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

1 Jun 2011
Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

1 Jun 2011
YM announces updates on nimotuzumab clinical development program

YM announces updates on nimotuzumab clinical development program

31 May 2011
Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

27 May 2011
Bayer, Epitomics enter service agreement for antibody technology

Bayer, Epitomics enter service agreement for antibody technology

27 May 2011
Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

25 May 2011
Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

24 May 2011
Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet's blinatumomab data to be presented at two upcoming medical meetings

23 May 2011
Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

21 May 2011
Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

21 May 2011
Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

21 May 2011
Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

20 May 2011
JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

18 May 2011
Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

18 May 2011
Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

17 May 2011
GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

17 May 2011
Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

16 May 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback